封面
市場調查報告書
商品編碼
1479910

血流動力學監測系統市場-2024年至2029年預測

Hemodynamic Monitoring Systems Market - Forecasts from 2024 to 2029

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 126 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022 年血液動力學監測系統市場的市場規模為 942,753,000 美元,預計在預測期內複合年成長率為 6.01%,到 2029 年達到 1,418,612,000 美元的市場規模。

血流動力學監測系統直接測量靜脈、心臟和動脈的血壓。它還會檢查您的血流量和氧氣水平。這些系統還包括用於記錄診斷導管插入、冠狀動脈、週邊和電生理學 (EP) 操作的介面。

微創技術支援連續監測每搏輸出量並提供動態液體反應性資訊。有些系統測量容量預載係數,而有些系統則使用專有導管連續監測中心靜脈飽和度。

血流動力學監測系統的技術進步、血流動力學監測系統研究的增加、創業投資資金的流入、心血管疾病和糖尿病盛行率的上升、老年人口的成長以及手術量的增加、行業意識提升的努力和政府推動了成長。

市場促進因素

  • 技術進步

近年來,侵入性技術已不再普及,人們越來越傾向於非侵入性選擇。非侵入性血流動力學監測技術可以實現無痛診斷,並限制患者感染血液傳染疾病的可能性。此外,與侵入性系統相比,這些系統侵入性較小,可以在沒有專家或醫生的情況下由護士操作。

這一優勢可同時監測多個患者的血流動力學,從而減少人員配備和治療成本。由於這些優勢,非侵入式系統的市場在未來幾年可能會成長。對於重症患者,非侵入性血流動力學監測需要用指套連續測量血壓,並用脈搏輪廓技術測量心摶出量。例如,Caretaker Medical 的 Caretaker 4 使用指套測量連續脈動血壓 (“cNIBP”)、心率和其他生理資料。

  • 心血管疾病增加

該市場主要受到心臟衰竭、冠狀動脈疾病和心律不整等慢性心血管疾病 (CVD) 盛行率不斷上升的推動。這些病理需要持續監測血流動力學參數,以確保有效的診斷、治療和管理。

根據《世界心臟報告》,心血管疾病影響全球超過 5 億人,到 2021 年將導致 2,050 萬人死亡。不健康的飲食、缺乏體力活動、吸煙和有害的飲酒已被確定為心臟病和中風最重要的行為危險因素。

老年人口不斷增加、不健康的生活方式和肥胖率上升等因素進一步加劇了心血管疾病的負擔。總的來說,這些因素導致對血流動力學監測的需求不斷增加,血流動力學監測是應對心血管疾病帶來的挑戰的基本要素。

市場限制:

  • 與侵入性血流動力學監測市場相關的風險。

除了侵入性監測(特別是插入肺動脈導管)帶來的不適之外,該手術還存在多種風險:敗血症、出血、心律不整、四肢遠端血液循環減少、出血、神經損傷(插入期間)。血栓症、空氣栓塞、肺毛細血管壞死。

這些因素會增加侵入性血流動力學手術期間的死亡率。因此,侵入性血流動力學監測僅提案用於有限的目的,假設在手術過程中獲取相關資料的好處超過了風險。

此外,不建議老年或體弱患者使用侵入性血流動力學監測方法。此外,侵入式血流動力學監測非常昂貴且需要由合格的專業人員將導管放置在患者體內。儘管有創血流動力學監測可以提供有關患者血流動力學狀態的準確、全面和連續的資料,但其使用受到上述風險的限制。

血流動力學監測系統市場按類型分為非侵入性、微創和侵入。

血流動力學監測系統市場分為非侵入性法、微創法和侵入法等類型。非侵入性監測適用於醫院病房、急診室、居家醫療等多種環境下的連續監測。

微創系統用於病情較嚴重的患者,例如在加護病房或某些醫療程序期間。侵入性監測僅限於重症患者,並在必要時包括高度準確和詳細的血流動力學測量。

預計北美將佔據血流動力學監測市場的主要佔有率。

北美是血流動力學監測市場的重要地區,在未來幾年仍將如此。由於知名市場參與企業的存在、技術先進的醫院的存在以及該地區醫院接受治療的重症患者數量不斷增加,血流動力學監測市場預計將發展最快。

由於 FDA 對監測設備的核准增加和新產品的發布,北美血流動力學監測市場在預測期內可能會擴大。

市場開拓:

  • 2023 年 7 月 - Retia Medical 宣布天普大學收購其 Argos 血流動力學監測儀。此次收購對於 Retia Medical 來說是一個顯著的里程碑,鞏固了該公司在學術和研究界的地位。
  • 2023年6月-邁瑞醫療與歐洲Edwards Lifesciences合作推出先進的血流動力學監測解決方案。這是兩家公司策略夥伴關係的一個重要里程碑。 Edwards Lifesciences 與邁瑞醫療 (Mindray Medical) 合作,邁瑞醫療是結構性心臟病和重症加護監測領域醫療創新的全球領導者,也是醫療設備和解決方案的領先提供者。
  • 2022 年 6 月 - 著名的高清無線超音波系統供應商 Clarius 行動醫療和血流動力學超音波專家ImaCor 宣布推出世界上首個手持式經食道超音波心動圖(TEE) 系統,並宣佈建立合作夥伴關係以推廣。這款突破性系統專為加護病房(ICU)重症患者的管理和護理指導而設計。這項突破性系統已獲得美國食品藥物管理局(FDA) 的批准,使臨床醫生能夠做出更快、更準確和明智的決策,從而幫助改善 ICU患者照護。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章血流動力學監測系統市場:依類型

  • 介紹
  • 非侵入性
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 微創
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 侵入性的
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章血流動力學監測系統市場:依產品

  • 介紹
  • 監視器
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 一次性的
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章血流動力學監測系統市場:依最終用戶分類

  • 介紹
  • 醫院/診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 門診治療中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 居家照護設置
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章血流動力學監測系統市場:按地區

  • 介紹
  • 北美洲
    • 按類型
    • 依產品
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按類型
    • 依產品
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按類型
    • 依產品
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 依產品
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 依產品
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Edward Lifesciences Corporation
  • GE Healthcare
  • Koninklijke Philips NV
  • Draeger
  • LiDCO Group PLC
  • Pulsion Medical Systems SE
  • ICU Medical, Inc.
  • Cheetah Medical, Inc.
  • CNSystems Medizintechnik GmbH
  • Schwarzer Cardiotek GmbH
簡介目錄
Product Code: KSI061611466

Hemodynamic Monitoring Systems Market was valued at US$942.753 million in 2022 and is expected to grow at a CAGR of 6.01% over the forecast period to reach a market size of US$1418.612 million by 2029.

Hemodynamic monitoring systems take blood pressure readings directly from the veins, heart, and arteries. They also check for blood flow and oxygen levels. These systems also include interfaces for recording diagnostic catheterizations, and coronary, peripheral, and electrophysiology (EP) operations.

The minimally invasive technologies aid in the continuous monitoring of stroke volume and provide dynamic fluid responsiveness information. Some of the systems measure volumetric preload factors, while others use proprietary catheters to continuously monitor central venous saturation.

The growth is being driven by technological advancements in hemodynamic monitoring systems, increased research into hemodynamic monitoring systems, an influx of venture capital funding, a rising prevalence of cardiovascular diseases and diabetes, a rising geriatric population & growing number of surgeries, industry awareness initiatives, and government focus on critical care infrastructure & services.

Market Drivers:

  • Technological advancements-

With an increasing preference for noninvasive alternatives, Invasive techniques have become less popular in recent years. Noninvasive hemodynamic monitoring technologies allow for painless diagnosis and limit the chance of patients contracting blood-borne diseases. Furthermore, these systems are less invasive and can be operated by a nurse in the absence of a professional or doctor as opposed to invasive systems.

Due to this advantage, the hemodynamic status of multiple patients can be monitored at the same time, resulting in lower staffing and treatment costs. The market for non-invasive systems is likely to grow in the next years due to these benefits. For critically ill patients, noninvasive hemodynamic monitoring requires continuous measurement of blood pressure with finger cuffs and measurement of cardiac output with the pulse contour method. The Caretaker 4 from Caretaker Medical, for example, measures continuous beat-by-beat blood pressure ("cNIBP"), heart rate, and other physiological data with a finger cuff.

  • Growing cardiovascular diseases-

The market is driven significantly by the increasing prevalence of chronic cardiovascular diseases (CVDs) such as heart failure, coronary artery disease, and arrhythmias. These medical conditions necessitate continuous monitoring of hemodynamic parameters to ensure effective diagnosis, treatment, and management.

According to the World Heart Report, more than half a billion people worldwide are affected by cardiovascular diseases, resulting in 20.5 million deaths in 2021. An unhealthy diet, physical inactivity, tobacco use, and harmful alcohol consumption are identified as the most critical behavioral risk factors for heart disease and stroke.

The rising burden of CVDs is further exacerbated by factors such as a growing geriatric population, unhealthy lifestyles, and increasing rates of obesity. These factors collectively contribute to an escalating demand for hemodynamic monitoring as an essential component in addressing the challenges posed by cardiovascular diseases.

Market Restraint:

  • Risks involved with invasive hemodynamic monitoring market-

Apart from the discomfort of invasive monitoring (particularly the insertion of the pulmonary artery catheter), there are several risks associated with this procedure: sepsis, bleeding, cardiac arrhythmias, reduced circulation to the distal limb, hemorrhage, nerve damage (during insertion), thrombosis, air embolism, and pulmonary capillary necrosis.

During invasive hemodynamic procedures, these factors increase the fatality rate. Hence, invasive hemodynamic monitoring is only suggested for a limited number of purposes, assuming that the risks are outweighed by the benefits of obtaining relevant data during the procedure.

Furthermore, invasive hemodynamic monitoring methods are not advised for elderly or weak patients. Furthermore, invasive hemodynamic monitoring is very costly and necessitates the use of qualified professionals to place catheters in patients. Even though invasive hemodynamic monitoring gives accurate, comprehensive, and continuous data regarding a patient's hemodynamic state, the risks described above limit its use.

The hemodynamic monitoring systems market is segmented by type into non-invasive, minimally invasive, and invasive

The market for hemodynamic monitoring systems is categorized by type, including non-invasive, minimally invasive, and invasive methods. Non-invasive monitoring is well-suited for continuous monitoring across diverse settings, such as hospital wards, emergency departments, and home care.

Minimally invasive systems are employed for more critically ill patients, typically in intensive care units and during specific medical procedures. Invasive monitoring is reserved for critically ill patients, providing highly accurate and detailed hemodynamic measurements when required.

North America is anticipated to hold a significant share of the hemodynamic monitoring market-

North America is a significant region in the hemodynamic monitoring market and is likely to do so for a few more years. Due to the existence of prominent market participants, technologically advanced hospitals, and an increasing number of critically ill patients being treated in hospitals throughout the region, the hemodynamic monitoring market is expected to develop the most.

The North American hemodynamic monitoring market is likely to increase during the forecast period, thanks to rising FDA approvals for monitoring devices and new product releases.

Market Developments:

  • July 2023- Retia Medical announced the acquisition of its Argos hemodynamic monitor by Temple University. This acquisition marked a noteworthy milestone for Retia Medical, solidifying its presence in the academic and research communities. The expert medical professionals and researchers at Temple University gained access to the advanced Hemodynamic Monitoring capabilities of the Argos monitor, contributing to the enhancement of patient care.
  • June 2023- Mindray Medical announced the launch of an advanced hemodynamic monitoring solution in collaboration with Edwards Lifesciences in Europe. This marked a significant milestone in their strategic cooperation agreement. Edwards Lifesciences, a global leader in medical innovations for structural heart disease and critical care monitoring, collaborated with Mindray Medical, a leading medical device and solution provider. The milestone involved integrating the Edwards FloTracTM sensor for hemodynamic monitoring into Mindray's flagship BeneVision N series patient monitors.
  • June 2022- Clarius Mobile Health, a prominent provider of high-definition wireless ultrasound systems, and ImaCor Inc., a company specializing in hemodynamic ultrasound, announced a partnership that facilitated the introduction of the world's first handheld transesophageal echocardiography (TEE) system. This innovative system was specifically designed for managing and guiding care for critically ill patients in the Intensive Care Unit (ICU). This groundbreaking system received clearance from the U.S. Food and Drug Administration (FDA), empowering clinicians to make informed decisions promptly and accurately, thereby enhancing patient care in the ICU.

Market Segmentation:

By Type

  • Non-invasive
  • Minimally-invasive
  • Invasive

By Product

  • Monitors
  • Disposables

By End-user

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Home Care Settings

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HEMODYNAMIC MONITORING SYSTEMS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Non-invasive
    • 5.2.1. Market opportunities and trends
    • 5.2.2. Growth prospects
    • 5.2.3. Geographic lucrativeness
  • 5.3. Minimally-invasive
    • 5.3.1. Market opportunities and trends
    • 5.3.2. Growth prospects
    • 5.3.3. Geographic lucrativeness
  • 5.4. Invasive
    • 5.4.1. Market opportunities and trends
    • 5.4.2. Growth prospects
    • 5.4.3. Geographic lucrativeness

6. HEMODYNAMIC MONITORING SYSTEMS MARKET BY PRODUCT

  • 6.1. Introduction
  • 6.2. Monitors
    • 6.2.1. Market opportunities and trends
    • 6.2.2. Growth prospects
    • 6.2.3. Geographic lucrativeness
  • 6.3. Disposables
    • 6.3.1. Market opportunities and trends
    • 6.3.2. Growth prospects
    • 6.3.3. Geographic lucrativeness

7. HEMODYNAMIC MONITORING SYSTEMS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
    • 7.2.1. Market opportunities and trends
    • 7.2.2. Growth prospects
    • 7.2.3. Geographic lucrativeness
  • 7.3. Ambulatory Care Centers
    • 7.3.1. Market opportunities and trends
    • 7.3.2. Growth prospects
    • 7.3.3. Geographic lucrativeness
  • 7.4. Home Care Settings
    • 7.4.1. Market opportunities and trends
    • 7.4.2. Growth prospects
    • 7.4.3. Geographic lucrativeness

8. HEMODYNAMIC MONITORING SYSTEMS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By End-user
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Trends and Opportunities
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Trends and Opportunities
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Trends and Opportunities
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Product
    • 8.3.3. By End-user
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Trends and Opportunities
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Trends and Opportunities
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Trends and Opportunities
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Product
    • 8.4.3. By End-user
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Trends and Opportunities
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Trends and Opportunities
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Trends and Opportunities
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Trends and Opportunities
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Trends and Opportunities
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Trends and Opportunities
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Product
    • 8.5.3. By End-user
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Trends and Opportunities
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Trends and Opportunities
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Trends and Opportunities
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Product
    • 8.6.3. By End-user
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Trends and Opportunities
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Trends and Opportunities
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Trends and Opportunities
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Trends and Opportunities
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Trends and Opportunities
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Trends and Opportunities
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Trends and Opportunities
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Trends and Opportunities
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisition, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Edward Lifesciences Corporation
  • 10.2. GE Healthcare
  • 10.3. Koninklijke Philips N.V.
  • 10.4. Draeger
  • 10.5. LiDCO Group PLC
  • 10.6. Pulsion Medical Systems SE
  • 10.7. ICU Medical, Inc.
  • 10.8. Cheetah Medical, Inc.
  • 10.9. CNSystems Medizintechnik GmbH
  • 10.10. Schwarzer Cardiotek GmbH